Background
==========

Based on statistics collected by the [@ref-8], approximately 33,700 incidences of cancer per year are associated with human papillomavirus (HPV) infection. HPV is considered a leading cause of cervical cancers ([@ref-41]), respiratory papilloma, as well as of several types of cancers of the vagina, vulva, penis, anus, rectum and oropharynx ([@ref-22]; [@ref-25]). To prevent HPV infection and HPV related cancers ([@ref-4]; [@ref-12]; [@ref-36]), an HPV vaccine was first introduced in 2006 and has demonstrated its effectiveness based on post-market surveillance data. Studies showed that HPV vaccines contributed to a 64% reduction in vaccine-type HPV infections among teenage girls in the U.S. ([@ref-6]) and potentially prevents 31,200 (90%) HPV related cancers per year ([@ref-8]). According to CDC guidelines, HPV vaccines can be given to people beginning at age 9 years and is recommended for ages 11 through 26 ([@ref-5]). Ideally people should receive the HPV vaccines before they become sexually active and are exposed to HPV ([@ref-5]). In 2018 the U.S. Food and Drug Administration (FDA) expanded the approved use of the HPV vaccine to include women and men aged 27 through 45 years ([@ref-16]). With the increase in HPV vaccination coverage ([@ref-9]; [@ref-11]), pharmacovigilance should be further strengthened.

The distribution and cause of adverse events (AEs) has been an integral topic of pharmacovigilance ([@ref-14]; [@ref-21]; [@ref-37]; [@ref-42]). Post market surveillance is one of the common approaches to investigate vaccine AEs ([@ref-29]). The Vaccine Adverse Event Reporting System (VAERS), a national early warning system that detects potential safety concerns in U.S. licensed vaccines ([@ref-39]), is one of the popular resources explored by various post-market vaccine safety studies ([@ref-20]; [@ref-24]; [@ref-31]; [@ref-34]; [@ref-43]). The topics of these studies ranged from validating results of clinical research ([@ref-3]; [@ref-19]; [@ref-27]; [@ref-35]), general description of AE types ([@ref-26]), identifying safety signals and causal relationships ([@ref-13]; [@ref-17], [@ref-18]; [@ref-28]; [@ref-32]), AEs and differences in categories of AE across races ([@ref-23]). However, none of these studies investigated the association between the variation in HPV vaccination related AE categories and age or gender. In addition, the correlation or clustering among AE categories is underexplored, though it has been studied using a data source other than VAERS ([@ref-10]).

This article reports on a retrospective observational study aimed to address the major two knowledge gaps above. In addition to identify differences among AEs, the novelty of this study was that it explored the underlying relationship among AEs, which could potentially advance future investigation into the biological or clinical relevance of these relationships. The investigation was based on the HPV vaccine AE records extracted from the VAERS database between 2006 and 2017.

Materials and Methods
=====================

Methods overview
----------------

We implemented a retrospective observational study based on the VAERS data to address the following research questions: (1) Are the frequencies of AEs different across different gender and age groups? If significant differences are observed, it is essential to develop a more precise vaccine information statement for these targeted subgroups. (2) Are there any correlations among the AEs? Specifically, we explored whether some AEs were more likely to occur together. This study included subjects aged between 9 and 25 years old who received the following vaccine types: HPVX/HPV2/HPV4/HPV9 (HPV vaccine with no brand name/HPV Cervarix/HPV Gardasil/HPV Gardasil 9). We excluded records with any missing information regarding age, gender or symptoms. The final eligible sample size was 26,023 including 21,647 females and 4,376 males.

Data source mapping symptoms in VAERS
-------------------------------------

Vaccine Adverse Event Reporting System database included nearly 47,000 reports associated with a HPV vaccine as of December 2017. AE symptoms were annotated following the guidelines of Medical Dictionary for Regulatory Activities (MedDRA) ([@ref-15]). MedDRA is a standardized medical terminology for medical products. MedDRA consists of a five-level structural hierarchy: system organ classes (SOC), high level group term, high level term, prefer term (PT), lowest level term (LLT) ([@ref-44]). The AE symptoms in the VAERS dataset were annotated using the PT level terms. To map PT level AE to SOC level, we followed the method from a previous study and developed a dictionary-like lookup table by using the internationally agreed upon order of the SOC list ([Table 1](#table-1){ref-type="table"}) ([@ref-14]). The sort of the list is based upon the relative importance of each SOC, which was determined by the Expert Working Group ([@ref-30]). The "dictionary" converts the symptoms at the PT level in VAERS to a corresponding unique SOC. Based on the data update, the "dictionary" has been expanded and refined in a new round ([Fig. 1](#fig-1){ref-type="fig"}).

![The flowchart of project.\
(A) was to map AEs from MedDRA PT level to MedDRA SOC level. (B) was to apply statistical models on mapped AEs.](peerj-07-7490-g001){#fig-1}
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###### The SOC list.

The MedDRA Terminology SOC List---Internationally Agreed Order. MedDRA Management Board endorsed the creation of an additional 27th SOC category named "product issue" in 2016. It has no major impact on this research.
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  No.    SOC
  ------ --------------------------------------------------------------------------
  1      Infections and infestations
  2      Neoplasms benign, malignant and unspecified (including cysts and polyps)
  3      Blood and lymphatic system disorders
  4      Immune system disorders
  5      Endocrine disorders
  6      Metabolism and nutrition disorders
  7      Psychiatric disorders
  8      Nervous system disorders
  9      Eye disorders
  10     Ear and labyrinth disorders
  11     Cardiac disorders
  12     Vascular disorders
  13     Respiratory, thoracic and mediastinal disorders
  14     Gastrointestinal disorders
  15     Hepatobiliary disorders
  16     Skin and subcutaneous tissue disorders
  17     Musculoskeletal and connective tissue disorders
  18     Renal and urinary disorders
  19     Pregnancy, puerperium and perinatal conditions
  20     Reproductive system and breast disorders
  21     Congenital, familial and genetic disorders
  22     General disorders and administration site conditions
  23     Investigations
  24     Injury, poisoning and procedural complications
  25     Surgical and medical procedures
  26     Social circumstances
  27\*   Product issues

There are 27 SOC categories defined by MedDRA. However, since the "product issue" category does not describe AEs in humans, any AE that belonged to this category was excluded from the analyses. Therefore, 26 SOCs was included in this study.

Statistical methods
-------------------

Our analyses consisted of two major inter-coherent parts based on the retrospective cohort study design. The first part was to address the hypothesis whether individual SOC level AEs contributed to the total AE reports differently, and whether age and gender profiles vary across these individual SOC AEs. In addition to investigate the difference, in the second part of the analyses we explored the hypothesis that correlations or clustering patterns might exist among some AE categories, and examined the lower AEs term (PT level) that contributed to these potential observed correlations.

Corresponding to the analyses scheme part one, an independent *t*-test was performed to assess the age distribution across gender and specific SOCs. A multivariate logistic regression model was developed to evaluate the risk of developing a specific SOC, accounting for potential confounding effects by age and gender. Odds ratio (OR) greater than 1 indicates an increased odd of getting a specific SOC, whilst a less than 1 OR suggests decreased odds. A zero truncated Poisson regression model was used to model the number of events because patients need to have at least one AE in order to be captured by the VAERS system. Zero truncated Poisson regression model was performed to assess the number of individual SOC cases per year adjusted for gender and age.

For any SOCs that were statistically significant from either the logistic regression model or zero truncated Poisson regression model, the lower-level symptoms (PT) attributed to these SOCs were further investigated using the multivariate logistic regression model adjusted for age and gender.

Finally, corresponding to the analyses scheme part two, pairwise Pearson correlation and un-supervised hierarchy clustering analyses were conducted to explore the interrelationships and clustering patterns across AEs. The analyses were first based on SOC level to identify the general pattern of the high-level AEs. Then PT level clustering analyses were performed on the SOC level AE that contributed to the majority of the AE cases and its most correlated three SOC level AEs. The hierarchical clustering method is based on the Euclidean distance between the vectors of Pearson correlation using a complete linkage algorithm. The optimal number of clusters was determined by the average silhouette method ([@ref-33]). Correlation network figures were then developed to summarize findings regarding correlation strength and clustering patterns of the PT level AEs. Only those with statistically significantly weak or above correlation (*r* \> 0.2) are included in the Figures. Statistical significance level was defined as adjusted *p*-value \< 0.05, after accounting for multiple testing using the Holm method ([@ref-1]). The details of the Holm method have been discussed elsewhere, in general, it controls type-I error (false positive) in a less conservative way than Bonferroni correction ([@ref-2]) with lowered risks in type II error (false negative).

All statistical analyses were based on R version 3.5.1 ([@ref-45]).

Results
=======

[Table 2](#table-2){ref-type="table"} lists the age distribution of SOCs by gender evaluated through independent *t*-test. Overall, the first vaccination age of females was relatively older than males according to the VAERS data (16.318 vs 14.14, 95% CI \[2.073--2.283\]), the difference was statistically significant (*p* \< 0.0019). Similar distribution was observed across all individual SOC subgroups. The age difference was statistically significant among all SOCs except for neoplasms benign, malignant and unspecified (including cysts and polyps), ear and labyrinth disorders, hepatobiliary disorders and social circumstances.
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###### Age distribution of SOCs by gender, VAERS 2006--2017[\*](#table-2fn1){ref-type="fn"}.
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  SOC                                                    Female mean age   Male mean age   Mean difference (95% CI)   *p*-value[\*\*](#table-2fn2){ref-type="fn"}   Sample size   
  ------------------------------------------------------ ----------------- --------------- -------------------------- --------------------------------------------- ------------- --------
  ALL                                                    16.318            14.14           2.073                      2.283                                         \<0.001       26,023
  Nervous system disorders                               15.853            14.506          1.202                      1.492                                         \<0.001       12,369
  General disorders and administration site conditions   16.327            13.762          2.402                      2.727                                         \<0.001       10,537
  Skin and subcutaneous tissue disorders                 15.935            13.342          2.4                        2.785                                         \<0.001       6,688
  Investigations                                         16.792            14.991          1.519                      2.08                                          \<0.001       5,790
  Gastrointestinal disorders                             16.277            14.248          1.773                      2.284                                         \<0.001       4,706
  Musculoskeletal and connective tissue disorders        16.554            14.769          1.471                      2.098                                         \<0.001       4,241
  Immune system disorders                                16.169            14.144          1.742                      2.307                                         \<0.001       3,802
  Injury, poisoning and procedural complications         15.941            14.74           0.91                       1.49                                          \<0.001       2,791
  Psychiatric disorders                                  15.846            14.301          1.227                      1.864                                         \<0.001       2,711
  Vascular disorders                                     15.776            14.243          1.229                      1.837                                         \<0.001       2,650
  Infections and infestations                            16.793            14.347          1.868                      3.022                                         \<0.001       1,962
  Cardiac disorders                                      16.497            14.376          1.694                      2.547                                         \<0.001       1,803
  Metabolism and nutrition disorders                     16.113            13.331          2.245                      3.32                                          \<0.001       1,178
  Respiratory, thoracic and mediastinal disorders        15.913            14.113          1.276                      2.324                                         \<0.001       1,083
  Surgical and medical procedures                        17.42             14.8            1.95                       3.286                                         \<0.001       979
  Blood and lymphatic system disorders                   16.779            15.176          0.782                      2.423                                         0.002         773
  Social circumstances                                   16.181            15.173          0.072                      1.945                                         0.106         625
  Eye disorders                                          15.511            14.505          0.281                      1.731                                         0.034         621
  Reproductive system and breast disorders               17.574            14.357          1.661                      4.772                                         0.004         565
  Endocrine disorders                                    16.55             14.5            0.751                      3.35                                          0.032         537
  Ear and labyrinth disorders                            16.069            15.808          −1.381                     1.904                                         0.847         228
  Neoplasms benign, malignant and unspecified            16.769            13.583          0.873                      5.499                                         0.044         220
  Renal and urinary disorders                            16.324            13.882          1.037                      3.847                                         0.011         205
  Hepatobiliary disorders                                16.917            16.2            −1.182                     2.615                                         0.847         53

**Notes:**

SOCs congenital, familial and genetic disorders and pregnancy, puerperium and perinatal conditions were not included because their cases were exclusively females.

*p*-value was adjusted for multiple testing using Holm method.

[Table 3](#table-3){ref-type="table"} illustrates the association between the rate of developing any SOCs across gender and age. The interaction term between gender and age from the pooled model was statistically significant (*p* \< 0.0019), which indicated the effect of age on developing any SOCs varied by gender. The subsequent stratification analyses shed further light on the difference of the effect by age variable. As shown in the male-only Poisson Regression model, with 1-year increase in age, the rate of developing SOCs among the observed cohort increased by 0.01 cases per person-year. In contrast, in the female-only model, each 1-year increase in age was associated with 0.004 decrease case per person-year on average.
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###### Zero truncated Poisson regression of total population and by gender.

The association between the rate of developing any SOCs across gender and age.
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                                 Coefficient   *p*-value
  -------- --------------------- ------------- -----------
  Pooled   Age (Years)           −0.004        \<0.001
           Male (Ref: Female)    −0.482        \<0.001
           Age (Years) \* Male   0.014         \<0.001
  Male     Age (Years)           0.010         \<0.001
  Female   Age (Years)           −0.004        \<0.001

[Table 4](#table-4){ref-type="table"} presents the odds of developing specific SOCs adjusting for gender, age and interaction term between gender and age. This table only includes top 10 SOCs with which contributed to the most AE. A complete table of 24 SOCs can be found in [Table S1](#supp-1){ref-type="supplementary-material"}. Using nervous system disorders as an example for the interpretation of effects of the three variables: Among females, each 1 year increase in age is associated with 0.055 (1 − exp(−0.057 × 1 + 0.131 × 1 × 0)) decrease in the odds of developing nervous system disorders. In contrast, among males, each 1 year increase in age is associated with (exp(−0.057 × 1 + 0.131 × 1 × 1) − 1) 0.077 increased odds of developing nervous system disorders.
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###### Logistic Regression by Individual SOCs adjusted for gender, age and interaction term between gender and age.

The odds of developing specific SOCs adjusting for gender, age and interaction term between gender and age. This table only includes top 10 SOCs with which contributed to the most AE. A complete table of 24 SOCs can be found in [Table S1](#supp-1){ref-type="supplementary-material"}.
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  No.                                                                                                Coefficient   Standard error   *p*-value
  --------------------------- ------------------------------------------------------ --------------- ------------- ---------------- -----------
  4                           Immune system disorders                                Age (in Year)   −0.011        0.005            0.225
  Gender (Male:1, Female:0)   −0.35                                                  0.227           1.000                          
  Age \* Gender               0.012                                                  0.015           1.000                          
  7                           Psychiatric disorders                                  Age (in Year)   −0.034        0.006            \<0.001
  Gender (Male:1, Female:0)   −0.951                                                 0.259           0.004                          
  Age \* Gender               0.053                                                  0.018           0.043                          
  8                           Nervous system disorders                               Age (in Year)   −0.057        0.003            \<0.001
  Gender (Male:1, Female:0)   −2.018                                                 0.157           \<0.001                        
  Age \* Gender               0.131                                                  0.011           \<0.001                        
  12                          Vascular disorders                                     Age (in Year)   −0.039        0.006            \<0.001
  Gender (Male:1, Female:0)   −0.737                                                 0.249           0.043                          
  Age \* Gender               0.052                                                  0.017           0.039                          
  14                          Gastrointestinal disorders                             Age (in Year)   −0.003        0.004            1.000
  Gender (Male:1, Female:0)   −0.534                                                 0.213           0.148                          
  Age \* Gender               0.017                                                  0.014           1.000                          
  16                          Skin and subcutaneous tissue disorders                 Age (in Year)   −0.033        0.004            \<0.001
  Gender (Male:1, Female:0)   1.725                                                  0.181           \<0.001                        
  Age \* Gender               −0.106                                                 0.013           \<0.001                        
  17                          Musculoskeletal and connective tissue disorders        Age (in Year)   0.018         0.004            0.001
  Gender (Male:1, Female:0)   −1.134                                                 0.226           \<0.001                        
  Age \* Gender               0.054                                                  0.015           0.006                          
  22                          General disorders and administration site conditions   Age (in Year)   0.001         0.003            1.000
  Gender (Male:1, Female:0)   1.236                                                  0.159           \<0.001                        
  Age \* Gender               −0.075                                                 0.011           \<0.001                        
  23                          Investigations                                         Age (in Year)   0.039         0.004            \<0.001
  Gender (Male:1, Female:0)   −1.465                                                 0.215           \<0.001                        
  Age \* Gender               0.058                                                  0.014           0.001                          
  24                          Injury, poisoning and procedural complications         Age (in Year)   −0.027        0.006            \<0.001
  Gender (Male:1, Female:0)   −1.011                                                 0.22            \<0.001                        
  Age \* Gender               0.097                                                  0.014           \<0.001                        

As for PT level analyses, nervous system disorders was targeted because it contributed to the most adverse events (12,378) in VAERS data. As shown in [Table 5](#table-5){ref-type="table"}, a disproportional reporting of PT level terms was found between the genders. For example, males experienced fewer headaches and hypoesthesia than females, 19.40% vs 24.20% and 3.97% vs 7.9%, respectively.
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###### Chi-square test of PT level symptoms from nervous system disorders[\*](#table-5fn1){ref-type="fn"}.
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  ------------------------------------------------------------------------------
                                  Female   Male    *p*-value           
  ----------------------- ------- -------- ------- ----------- ------- ---------
  Dizziness               No      6,982    67.50   1,359       66.70   0.454

  Yes                     3,357   32.50    680     33.30               

  Syncope                 No      7,348    71.10   1,470       72.10   0.365

  Yes                     2,991   28.90    569     27.90               

  Headache                No      7,838    75.80   1,644       80.60   \<0.001

  Yes                     2,501   24.20    395     19.40               

  Loss of consciousness   No      8,866    85.75   1,716       84.16   0.067\

  Yes                     1,473   14.25    323     15.84               

  Hypoaesthesia           No      9,522    92.10   1,958       96.03   \<0.001

  Yes                     817     7.90     81      3.97                
  ------------------------------------------------------------------------------

**Note:**

Only top five PT-level terms were demonstrated.

[Figure 2](#fig-2){ref-type="fig"} illustrates the overall correlation among the 26 SOCs. The majority of the SOCs seem to be positively connected except five pairs which demonstrate weak negative correlation (skin and subcutaneous tissue disorders + injury poisoning and procedural complications; skin and subcutaneous tissue disorders + nervous system disorders; skin and subcutaneous tissue disorders + pregnancy, puerperium and perinatal conditions; nervous system disorders + pregnancy, puerperium and perinatal conditions; pregnancy, puerperium and perinatal conditions + general disorders and administration site conditions).

![Correlation Network of 26 SOCs.\
The overall correlation among the 26 SOCs. The colors of the nodes differentiate the clusters of each SOC, which is determined by the hierarchical clustering analyses using a complete linkage algorithm.](peerj-07-7490-g002){#fig-2}

[Figures 3](#fig-3){ref-type="fig"}--[5](#fig-5){ref-type="fig"} show the PT-level interrelationship among AEs from four SOC groups: nervous system disorders, psychiatric disorders, gastrointestinal disorders and musculoskeletal and connective tissue disorders. The first one contributed the most AEs while the other three demonstrate clinical relevance and strongest correlation with nervous systems disorders (*r* = 0.357, 0.215, 0.261, respectively). The figures only display those AEs with Pearson correlation *r* \> 0.2, and adjusted *p*-value \< 0.05 (Holm method). An inter-SOCs correlation of the PTs was observed among nervous system disorders + psychiatric disorders and nervous system disorders + musculoskeletal and connective tissue disorders; the relatively strong correlations were not limited to PTs attributed to the same SOC category. For example, the correlation between Photophobia (nervous system disorders) and phonophobia (psychiatric disorders) was 0.38 (*p* \< 0.05). This frequently observed inter-SOCs correlation may be due to the close clinical relationship among these three SOCs. However, this pattern was much less common in pairs of nervous system disorders and gastrointestinal disorders. Most of the weak or above correlations (*r* \> 0.2) were found among PTs from the same SOC category. Only a few inter-SOCs correlation were identified, such as the pair of Intestinal obstruction and Migraine without aura (*r* = 0.41).

![Correlation network of pairwise Pearson correlation of PT-term level AEs from nervous system disorders and psychiatric disorders.\
The PT-level interrelationship among AEs from nervous system disorders and psychiatric disorders.](peerj-07-7490-g003){#fig-3}

![Correlation network of pairwise Pearson correlation of PT-term level AEs from nervous system disorders and gastrointestinal disorders.\
The PT-level interrelationship among AEs from nervous system disorders and gastrointestinal disorders.](peerj-07-7490-g004){#fig-4}

![Correlation network of pairwise Pearson correlation of PT-term level AEs from nervous system disorders and musculoskeletal and connective tissue disorders.\
The PT-level interrelationship among AEs from nervous system disorders and musculoskeletal and connective tissue disorders.](peerj-07-7490-g005){#fig-5}

As for the clustering analyses, most of the AEs were recommended to group into one large cluster, with the rest categorized into two small clusters. The PTs within the same cluster that demonstrated the most distinct clinical relevance were pancreatitis related AEs, abdominal rigidity, and gastrointestinal sounds abnormal (green cluster, [Fig. 4](#fig-4){ref-type="fig"}).

Discussion
==========

Our analyses revealed a variation in the distribution of AEs across gender and age groups. Generally, males reported AEs at younger first vaccination ages than females. None of the SOC level AEs which demonstrated statistical significance with age and gender met FDA\'s standards of serious AEs. On average, each person experienced four SOC level AEs. Among males, older vaccination age was associated with a slight increase in reported SOC level AEs, while the trend was reversed among females.

In the clustering analyses which investigated the top SOC subgroup nervous system disorders and its three most correlated AE subgroups psychiatric disorders, musculoskeletal and connective tissue disorders and gastrointestinal disorders, we identified many weak and above (*r* \> 0.2) inter subgroup correlation among PT pairs from nervous system disorders/psychiatric disorders and nervous system disorders/musculoskeletal and connective tissue disorders. However, the same level correlations among the pool of AEs by nervous system disorders and gastrointestinal disorders were mostly confined to PTs from the same SOC category. While the silhouette recommended that PT level AEs be divided into three clusters, whether such categorization is clinically informative demands further investigations.

The results of all of the statistical analyses from this study should be interpreted with caution. Since VAERS exclusively collected adverse reactions data (events post vaccination), the model based on its data only evaluates the risk or rate of developing specific adverse reactions among those who have already experienced adverse reactions. Our findings do not imply any real risk of developing adverse events after receiving HPV vaccination in the general population. Based on the CDC data, roughly half of adolescents received HPV vaccination by 2017 ([@ref-7]). Considering the 42 million population among the 10--19 years old group ([@ref-38]), we estimate the number of vaccinated adolescents to be approximately 21 million. This number should be even larger if considering the cohort effect (those who entered the adult cohort before 2017). However, only 26,023 adverse events were reported between 2006 and 2017 to VAERS, among which the non-serious AEs (dizziness, syncope, headache, etc. [Table 4](#table-4){ref-type="table"}) contributed to the majority. In addition, events such as Syncope, fainting and short-term loss of consciousness are common in adolescents regardless of the vaccination type. Therefore, our study didn\'t reveal any findings that contradict the current HPV vaccine safety profile.

The clustering pattern of the PT level terms was determined using the un-supervised learning methodology instead of clinical interpretations. Further studies are warranted to explore the biological pathways between the correlated adverse reactions. Due to the limitation as a passive surveillance system, issues such as under-reporting, over-reporting, inconsistent reporting quality etc. exist ([@ref-31]). Especially, VAERS accepts all reports without judging whether the event was caused by the vaccine ([@ref-40]). The observed statistical significance in the analyses does not imply cause-effect relationships and needs to be further validated in relevant clinical studies.

Conclusions
===========

To the best of our knowledge, this is the first investigation that systematically reviewed post-market safety profiles of HPV vaccines using VAERS data. The analyses revealed a different distribution pattern of AEs among different gender and age subgroups. This research contributes to the notion that the benefits of vaccination outweigh the potential risks.

We found 13 SOCs with significant differences in first vaccination. Based on the clustering analyses of selected AEs from nervous system disorders, psychiatric disorders, musculoskeletal and connective tissue disorders and gastrointestinal disorders, we identified inter-dependences among AEs from different SOC level categories. VAERS data provide valuable HPV vaccines safety data. However, findings from this study should be interpreted with caution. Further clinical studies are warranted to understand the heterogeneity of AEs reporting across subgroups and the biology pathways among the statistically correlated AEs.
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###### Logistic Regression by all SOCs adjusted for Gender, Age and Interaction Term Between Gender and Age.

The odds of 24 SOCs adjusting for gender, age and interaction term between gender and age.

###### 

Click here for additional data file.
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